Evaluating HN2301 for treating difficult cases of systemic lupus erythematosus

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to assess the safety and initial efficacy of HN2301 injections in patients with relapsing and refractory systemic lupus erythematosus (SLE). It is a prospective exploratory trial that includes individuals aged 18 to 69 who have been diagnosed with SLE and have not responded adequately to standard treatments. Participants must have a history of SLE for at least six months and have been on a stable treatment regimen for at least eight weeks. The study will monitor the participants for safety and effectiveness of the new treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients aged between 18 and 69 (inclusive), of any gender;
* Appropriate bone marrow, coagulation, cardiopulmonary, liver, and kidney functions. Bone marrow function: ANC ≥1.5×10\^9/L, ALC ≥0.8×10\^9/L, Hb ≥80g/L. No use of transfusions and growth factors allowed within 7 days prior to screening to meet these requirements. Coagulation function: INR or APTT ≤1.5×ULN. Cardiac function: Echocardiography (ECHO) assessment of left ventricular ejection fraction (LVEF) ≥40%. Lung function: ≤CTCAE grade 1 dyspnea and SpO2 ≥92% (measured by pulse oximetry) while breathing indoor air. Liver function: ALT and AST ≤2.5×ULN, total bilirubin \<2.0mg/dL (Gilbert syndrome subjects total bilirubin \<3.0mg/dL). Kidney function: defined as creatinine clearance rate (Cockcroft-Gault) ≥50mL/min without need for fluid assistance;
* Non-pregnant/non-lactating participants, willing to adopt contraceptive measures within 12 months after drug infusion;
* Diagnosed with SLE according to the 2019 EULAR/ACR SLE diagnostic criteria; A history of SLE for at least 6 months, having used a stable standard treatment regimen for at least 8 weeks; Oral corticosteroids are prednisone (or equivalent drug) ≥7.5mg/day and ≤30mg/day. At least two immunosuppressants have been used in a standardized manner (including hydroxychloroquine); Screening period tests meet: positive blood antinuclear antibody (ANA), and/or positive anti-ds-DNA antibodies, and/or hypocomplementemia;
* SSc-meets the classification criteria of ACR and EULAR, 10-35 in mRSS score;
* RA-meets the classification criteria of ACR and EULAR, DAS28-ESR\>3.2, ACPA possitive.

Exclusion Criteria:

* Individuals with positive Hepatitis B surface antigen (HBsAg) and/or Hepatitis B core antibody (HBcAb), and Hepatitis B virus (HBV) DNA positivity or titers above the detection threshold; those with positive Hepatitis C virus (HCV) antibodies and HCV RNA positivity or titers above the detection threshold; individuals with Human Immunodeficiency Virus (HIV) antibodies positivity, CMV DNA positivity or above the detection limit; those with positive syphilis antigen or antibodies;
* Presence of other uncontrolled active infections;
* History of major organ transplantation (such as heart, lung, liver, kidney) or bone marrow/hematopoietic stem cell transplantation;
* Pregnant or breastfeeding women;
* Receiving any mRNA-LNP product or other LNP medications within the past two years;
* History of any of the following cardiovascular diseases within the last 6 months before screening: Class III or IV heart failure defined by the New York Heart Association (NYHA), myocardial infarction, unstable angina, uncontrolled or symptomatic atrial arrhythmias, any ventricular arrhythmias, or other clinically significant cardiac diseases;
* History of live vaccine administration within the last 30 days;
* Individuals with asthma, severe allergies;
* Other conditions deemed inappropriate for participation in this clinical study by the investigator.

Where it's running

• The First Affiliated Hospital of University of Science and Technology of China
  Hefei, Anhui, China Recruiting

Study contacts

• Principal investigator: Zhu Chen, MD — The First Affiliated Hospital of University of Science and Technology of China
• Study coordinator: Zhu Chen, MD
• Email: doczchen@ustc.edu.cn
• Phone: +86055162284920

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Registry and biorepository for rheumatic diseases

  This study is collecting samples and health information from adults with rheumatic diseases at Yale clinics to help researchers learn more about these conditions and improve future treatments.

  Recruiting Yale University · New Haven, Connecticut · NCT04402086

• Registry for pregnant women with autoimmune diseases

  This study is trying to learn more about how autoimmune diseases affect pregnant women and their babies to help improve their health during and after pregnancy.

  Recruiting Duke University · Durham, North Carolina · NCT03276923

• Test of HBM7020 in healthy adults and adults with autoimmune diseases

  This first-in-human study tests whether HBM7020 is safe and how it acts in the body for people with autoimmune diseases like RA, SLE, Sjögren's, and SSc compared with healthy volunteers.

  Recruiting Phase 1 Otsuka Pharmaceutical Development & Commercialization, Inc. · Brisbane, Queensland · NCT07649265

• ABBV-519 in adults with SLE or RA: safety and how the drug moves through the body after IV and subcutaneous doses

  This early study tests how ABBV-519 behaves in the body and its safety for adults with SLE or RA after single escalating doses.

  Recruiting at 15 sites Phase 1 AbbVie · Anniston, Alabama and 14 other locations · NCT07607964

• Anti-CD19/BCMA universal CAR-T cell therapy for refractory autoimmune diseases

  This will try anti-CD19/BCMA universal CAR-T cell therapy in adults with refractory rheumatoid arthritis, dermatomyositis, systemic lupus, or systemic sclerosis to see if it is safe and can control their disease.

  Recruiting The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07558850

• Immun4Cure Cohort of Autoimmune Diseases

  A long-term, 500-person database and biobank is being built to study autoimmune diseases like RA, SLE, and scleroderma, plus healthy adults, using deep profiling and regular follow-ups over five years.

  Recruiting University Hospital, Montpellier · Montpellier · NCT07515638

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.